Nebenwirkungen · Filgrastim Hexal
Filgrastim HEXAL 30 MU/0.5 mL solution for injection or infusion in pre-filled syringe Filgrastim HEXAL 48 MU/0.5 mL solution for injection or infusion in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 14–15
HOS-209650 · Präparat HOS-154345
14 Adverse reactions MedDRA system organ Very common Common Uncommon Rare class (≥ 1/10) (≥ 1/100 to < 1/10) (≥ 1/1,000 to (≥ 1/10,000 to < 1/1,000) < 1/100) Injury, Transfusion poisoning and reactione procedural complications a See section c (Description of selected adverse reactions) b There have been reports of GvHD and fatalities in patients after allogeneic bone marrow transplantation (see section c) c Includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain d Cases were observed in the post-marketing setting in patients undergoing bone marrow transplant or PBPC mobilisation e Adverse events with higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T12:41:00Z · SHA-256 83b07123404f62aa7b58fc9646c7d49724612fc3405ea7378cdce408567ccc18 · Passage 1b9eb8a63e6d1c204814a0e1f640a71062411da6d0438b1315149fdbfbf1f40b · Zeichen 6479–7513 im Abschnitt